Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Company Angiomax

Executive Summary

FDA issues "approvable" letter May 11 for bivalirudin as an anticoagulant for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. In October 1998, FDA's Cardiovascular and Renal Drugs Advisory Committee declined to recommend the anticoagulant, formerly Hirulog, for approval (1"The Pink Sheet" Nov 2, 1998, p. 19)

You may also be interested in...



TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force

The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.

TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force

The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.

Medicines Company To Undertake Two Hirulog Studies After Cmte. Rejection

The Medicines Company is prepared to go ahead with two previously planned studies for Hirulog (bivalirudin) following an FDA advisory committee rejection of the anticoagulant.

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel